Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting

Srivastava, Shivani, Salter, Alexander I., Liggitt, Denny, Yechan-Gunja, Sushma, Sarvothama, Megha, Cooper, Kirsten, Smythe, Kimberly S., Dudakov, Jarrod A. +3 more·2019·Cancer Cell
DOI 10.1016/j.ccell.2019.02.003

Cited by (335)

Items 301–335 of 335

  1. Next-generation biocomputing: mimicking artificial neural network with genetic circuits
    Leo Chi U Seak, Owen Lok In Lo, Wade Chun-Wai Suen, Ming-Tsung Wu · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  2. Cellular immunotherapy of pancreatic ductal adenocarcinoma: Discovery and evaluation of novel target candidates
    Daniel Schäfer · 2021
  3. Brisbane River Expressways as Landscape Urbanism
    Glenn S. Thomas · 2001
  4. Non-Hodgkin Lymphoma CAR T Cells: Enhancement on Synnotch Signaling, GLUT1 expression, and PGC1a expression brings Potential Clinical Advancement in Therapy
    Jack He, Yijia Chen, Zhi Feng Etan Kiang, Lyndon Juntang Yang · 2022 · International Symposium on Artificial Intelligence for Medicine Sciences (ISAIMS)
  5. Unleashing the Potential of Natural Killer Cells in Immunotherapy for Glioblastoma and Brain Tumors
    Pooya Farhangnia, Hossein Khorramdelazad, Pouria Ghiaee, Soheil Rahmani Fard, Ali‐Akbar Delbandi · 2023 · Interdisciplinary cancer research
  6. Additional file 2 of Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing
    Hyatt Balke‐Want, Vimal Keerthi, Nikolaos Gkitsas-Long, Andrew G. Mancini, Gavin Kurgan, Carley Fowler, Peng Xu, Xikun Liu, Kyle Asano, Sunny Patel et al. · 2023 · Figshare
  7. Challenges and Recent Advances in NK-Mediated Adoptive Cell Therapies against Cancer
    Tianxiang Zhang · 2024 · IntechOpen eBooks
  8. Engineering programmable CAR-T cells with tunable controls as fail-safe mechanisms during cancer immunotherapy
    Mikail Dogan, Lina Kozhaya, Lindsey Placek, Ece Karhan, Mesut Yiğit, Christina Mohammed, Qi Zhao, Derya Unutmaz · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  9. Chimeric antigen receptor T-cell therapy in acute myeloid leukaemia: Novel therapeutic approaches to longstanding challenges
    H. Park, M. Simmonds, T. Chevassut, R. Morgan · 2024 · Gene Reports
  10. Single Cells Signal Non-self from Self via ‘XOR’ and ‘NOT EQUALS’ Logic in a Dimer of Dimers
    Rocky An, Manu Prakash · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  11. Additional file 1 of Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing
    Hyatt Balke‐Want, Vimal Keerthi, Nikolaos Gkitsas-Long, Mancini, Andrew G., Gavin Kurgan, Carley Fowler, Peng Xu, Xikun Liu, Kyle Asano, Sunny Patel et al. · 2023 · Figshare
  12. Efficient Production of Chimeric Antigen Receptor (CAR) T Cells with Transgenes Exceeding 10 kb Using Lentiviral Vectors
    Philipp C. Rommel, Nils W. Engel, Bruce L. Levine, Carl H. June · 2026 · Journal of Visualized Experiments
  13. SLP-76/LAT AND-gated CAR-T cells mediate highly specific and durable antitumor activity in pancreatic ductal adenocarcinoma with reduced gastric toxicity
    Teeranut Asavasupreechar, Yisheng Li, Mingzhen Cai, JingHong Chen, Shuyi Li, Xingyu Ma, Jiading Qin, Guocheng Zhong, Zheng Guo, Chuan Yu et al. · 2026 · Research Square
  14. Defining the differential contributions of CD4+ and CD8+ T cells to CAR T cell therapy against B cell malignancies
    Morgane Boulch · 2022 · theses.fr (ABES)
  15. Developing logic-gated CAR T cells for saferT-cell lymphoma therapy
    Estelle Bourbon · 2025 · theses.fr (ABES)
  16. Programmable Chimeric Antigen Receptor T Cell Circuits With DNA Computing for Precision Tumor Therapy
    Miao Zhang, Quan Zhang, Xin Yu, Yuhui Yan, Yueting Yu, Guangna Liu, Fenglin Wang, Xia Chu, Jian-Hui Jiang · 2026 · Angewandte Chemie
  17. Synthetic biology-driven innovations in triple-negative breast cancer: Integrating engineering design with targeted therapeutics
    Negar Saliani, Mohammad Saeid Hejazi, Sepideh Zununi Vahed, Elnaz Mehdizadeh Aghdam, Zeinab Mori, Nikoo Hasheminejad, Mohammad Daroon Parvar, Soheila Montazersaheb, Vida Ebrahimi · 2026 · Journal of Biotechnology
  18. Spatial Regulation of CAR Signaling Enables Logic-Gated Activity
    T. Nichakawade, B. Mog, A. Pearlman, Taha S. Ahmedna, Nikita Marcou, Ricardo Mora-Cartin, E. Watson, B. Lee, Sarah R. DiNapoli, N. Papadopoulos et al. · 2026 · bioRxiv
  19. The potential of B7-H3 as a new target for CAR-T therapy: Advancements, challenges and clinical perspectives
    Juelan Ye, Jingjing Sun, Jiafeng Hou, L X Zhang, Chunbiao Wu, Jianru Xiao · 2026 · Cancer Treatment and Research Communications
  20. Engineering CAR-T cells for solid tumors: overcoming antigenic, trafficking, and microenvironmental barriers
    Ziyan Kong, Jinke Wang · 2026 · Frontiers in Immunology
  21. CAR-T in solid tumors: Obstacles and potential strategies
    Ziyi Ding, Yize Li, Min Huang · 2026 · Acta Pharmaceutica Sinica B
  22. Current therapeutic interventions to target cancer stem cells for metastasis
    Priyancka Arora, Rakesh Bhatia, Sheetal Sharma, Anupam Sharma, Subhash C. Chauhan, Jagmohan Singh, A. Sharma · 2026 · International Journal of Clinical Oncology
  23. Logic-gated CARs: a unified framework for programmable cell-based delivery systems
    Pu-Sheng Wei, Zitao Ma, Evelyn Chang, Yu-Hsuan Tsai, Kuo‐Ching Mei · 2026 · Trends in biotechnology
  24. De novo discovery of a potent ROR1-binding macrocyclic peptide and its evaluation as a novel imaging probe
    Peiying Li, Tao Yang, Zhenxin Ma, Yujie Wu, Xing Cheng, Chunmei An, Ningning Pang, Zhide Guo, Xiaochun Xiong · 2026 · Chinese Chemical Letters
  25. Mathematical modeling and sensitivity analysis of synNotch–CAR T-cells identify engineering targets for dynamic tunability
    Alexander Diefes, Bashir Sbaiti, Maria-Veronica Ciocanel, Cameron M. Kim · 2026 · Mathematical Biosciences & Engineering
  26. Multipronged enhancement of CART cell activity against ROR1 neoantigen by inhibition of H3K27 methyltransferase EZH2
    Shengchun Wang, Cosimo Lobello, Pradeep Gupta, Roniya Francis, Aldana Vistarop, Bhaumik Shah, Sergio Zamora-Erazo, Fahad Ahmed, David Rushmore, Andrew Kalgren et al. · 2026 · Cell Reports Medicine
  27. CAR-T cell therapy for solid tumors: antigen landscape, biological barriers, and engineering strategies for clinical translation
    Qian Niu, Meng Li, Chengyi Zhang, Qian Li, Meng Wang, Andong Liu · 2026 · Frontiers in Immunology
  28. Toward the next generation of CAR T cell therapies for cancer
    Diren Usta, Crystal Lee Mackall · 2026 · Cancer Cell
  29. Neoantigenic receptor ROR1 promotes cell growth through diverse and complementary mechanisms
    Shengchun Wang, Shilpa Rao, Cosimo Lobello, David Rushmore, Bhaumik Shah, Suzanne Paley, Pradeep Kumar Gupta, Andrew Kalgren, Dinesh Singh, Neil V. Sen et al. · 2026 · Leukemia
  30. Synthetic Notch CD123 and CLL1 chimeric antigen receptor T-cells (CAR-T) target acute myeloid leukemia and reduce off-tumor effects associated with CLL1 CAR-T cells
    Rui Zhang, Na Chen, Mengnan Li, Qingxi Liu, Mingfeng Zhao · 2026 · Molecular Biomedicine
  31. DNA Logic-Gated Biosensing of the Tumor Microenvironment for Multicomponent Profiling and Programmable Molecular Decision-Making
    Minghan Li, Yinuo Chen, Yihang Du, Yicong Li, Jinpeng Shi, Jie Tong, Yinan Li, Jiashuang Xu, Qiuyue Wu, Shengyuan Deng et al. · 2026 · Chemosensors
  32. Innovations and emerging trends in adoptive cell therapies for solid tumors: engineering strategies and clinical translation
    Peng Huang, WenLin Wu, Yu Min, Yi Zhang, YunFeng Tao, Zheran Liu, Zhigong Wei, Xingchen Peng · 2026 · Experimental Hematology and Oncology
  33. BindingDB Entry 50023829: Optimization of 1-Methyl-3-(pyridin-3-yl)-1H-indol Derivatives as ROR1 Inhibitors with Improved Activity and Selectivity.
    BindingDB · 2026 · UC San Diego
  34. Key Considerations for In Vitro Assessment of On- and Off-target/ Off-Disease Effects of Chimeric Antigen Receptor T-Cell Therapies
    Shari A. Price, Alberto del Rio, George Papadopoulos, Jonathan M. Clingan, Yi Yang, Louise S. Brackenbury, Sara Compte Sancerni, David Cobeta Lopez, Sabrina de Munnik, Louise Delsing et al. · 2026 · Cytotherapy
  35. From telomere dysfunction to seno-antigen selection: a conceptual framework and route-specific evidence appraisal for senolytic immunotherapy
    Sarfaraz K. Niazi · 2026 · Frontiers in Systems Biology